Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
复制标题
DOI：
10.1080/13543784.2021.1948532
复制
发表时间：
2021-07-01
影响因子：
6.1
通讯作者：
Brandi, Giovanni
中科院分区：
文献类型：
--
作者：
Rizzo, Alessandro;Dadduzio, Vincenzo;Brandi, Giovanni
前言：十多年来，索拉非尼单一疗法一直是晚期肝细胞癌患者治疗的主流，但新药和联合疗法最近带来了前所未有的范式转变。Lenvatinib联合Pembrolizumab目前正在被评估为晚期肝癌患者的一线治疗方案；早期临床试验已经报告了有希望的结果。涉及的领域：本文综述了联合应用Lenvatinib和Pembrolizumab治疗晚期肝细胞癌。检查了临床前的基本原理和已完成的和正在进行的试验，然后，作者反思了预测对基于免疫的组合的反应的生物标记物，以及基于这些新疗法提供的耐受性和临床益处的未来治疗决策。2021年4月对Pubmed/Medline、Cochrane图书馆和Scope us数据库进行了文献检索，并对国际癌症会议的摘要进行了综述。专家观点：新代理商和组合的格局继续扩大。最近，具有里程碑意义的IMbrave150试验证明，基于免疫的联合疗法在晚期肝癌治疗中取得了重要成果。基于早期临床试验的有希望的结果，lenvatinib加pembrolizumab有可能在这种情况下代表一种新的治疗选择。
Introduction: While sorafenib monotherapy represented the mainstay of medical treatment for advanced hepatocellular carcinoma (HCC) patients for more than a decade, novel agents and combination therapies have recently produced unprecedented paradigm shifts. The combination of lenvatinib plus pembrolizumab is now being evaluated as a front-line treatment in advanced HCC patients; early phase clinical trials have already reported promising results. Areas covered: This paper reviews the combination of lenvatinib plus pembrolizumab for the treatment of advanced HCC. The preclinical rationale and completed and ongoing trials are examined and later, the authors reflect on biomarkers of predictive of response to immune-based combinations and future treatment decision-making on the basis of tolerability and clinical benefits provided by these novel therapeutics. A literature search was conducted in April 2021 of Pubmed/Medline, Cochrane library and Scopus databases; moreover, abstracts of international cancer meetings were reviewed. Expert opinion: The landscape of new agents and combinations continues to expand. Recently, immune-based combinations have reported important results in advanced HCC, as witnessed by the landmark IMbrave150 trial. Based on the promising results of early phase clinical trials, lenvatinib plus pembrolizumab has the potential to represent a novel treatment option in this setting.